CME Group Director Makes a Noteworthy Stock Sale

New insider activity at CME Group ( (CME) ) has taken place on May 24, 2025.

Director Daniel Kaye recently executed a transaction involving the sale of 500 shares of CME Group stock, amounting to a total value of $141,205.

Recent Updates on CME stock

In the last 24 hours, CME Group has experienced significant developments impacting its stock. Erste Group downgraded CME Group to Hold from Buy, citing a slowdown in the company’s growth in turnover and net profit for the current and next year. Meanwhile, Argus raised its price target for CME Group, driven by the company’s record-breaking financial results in Q1 2025, where revenue reached $1.6 billion, a 10% increase from the previous year, and an all-time high average daily volume of 29.8 million contracts. The company’s robust performance was attributed to increased demand for its products amid economic uncertainty, with notable growth in commodities and financials. Additionally, CME Group announced the launch of XRP futures, expanding its crypto derivatives suite, which is expected to enhance its product offerings. Despite some challenges related to increased margin requirements and specific market segments, CME Group’s overall accomplishments and strategic growth initiatives suggest a promising future.

Spark’s Take on CME Stock

According to Spark, TipRanks’ AI Analyst, CME is a Outperform.

CME Group’s strong financial performance and positive earnings outlook are key strengths, supported by strategic corporate actions like the OSTTRA sale. While technical indicators suggest a bullish trend, potential overbought conditions should be monitored. The company’s valuation is reasonable, reflecting robust growth prospects.

To see Spark’s full report on CME stock, click here.

More about CME Group

YTD Price Performance: 22.03%

Average Trading Volume: 2,638,693

Technical Sentiment Signal: Buy

Current Market Cap: $101.6B